We're available 24/7. Call us anytime. (888) 552-6760
(888) 552-6760 SCHEDULE AN APPOINTMENT

Guido Marcucci,

Professor and Chair, Department of Hematologic Malignancies Translational Science

Biography photo
Location
Duarte Comprehensive Cancer Center
1500 East Duarte Road
Duarte, CA 91010
Specialties
Hematologic Oncology
Education
Medical school:
Board Certifications

  • Internal Medicine

  • Oncology

Degrees

  • 1986, M.D. Catholic University of the Sacred Heart, Rome, Italy

Fellowship

  • 1995-1997, Medical Oncology Fellowship, Dept. of Medicine, Roswell Park Cancer Institute, Buffalo, NY

  • 1990, Internal Medicine Fellowship, Regione Lazio, Italy

Residency

  • 1990-1993,  Internship and Residency in Internal Medicine, State University of New York, Buffalo, N.Y.

  • 1986-1989 Residency in Dermatology, Dept. of Dermatology, Catholic University of the Sacred Heart, Rome, Italy

Internship

  • 1990-1993, Internship and Residency in Internal Medicine, State University of New York, Buffalo, NY

Professional Experience

  • 2020-present, Chief, Division of Leukemia

  • 2017-2020, Chair and Professor, Department of Hematologic Malignancies Translational Science, Beckman Research Institute of City of Hope, Duarte, CA

  • 2014-present, Associate Director of Basic Research, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA

  • 2014-present, Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2014– present, Director, Hematopoietic Tissue Biorepository (HTB)

  • 2009-2014, Professor of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, and Pharmaceutics Division Hematology, Comprehensive Cancer Center and The Ohio State University, Columbus, OH

Academic Appointments
  • Vice Chair, Department of Hematology
  • Chief, Division of Leukemia
  • Chair and Professor, Department of Hematologic Malignancies Translational Science
  • Director, Gehr Family Center for Leukemia Research
  • Professor, Department of Hematology & Hematopoietic Cell Transplantation
  • Director, Hematopoietic Tissue Biorepository (HTB)
About Me
I have always been interested in answering the fundamental questions of what events initiate cancer, and I believe that leukemia can be used as a model to answer these questions.
 
Guido Marcucci, M.D., thinks of acute myeloid leukemia as the “prototype of cancer and how cancer develops,” which makes it a prime target for intensive research, and the focus of much of Dr. Marcucci's distinguished career.
 
Dr. Marcucci joined City of Hope in 2014 from The Ohio State University, where he was a professor of internal medicine, molecular virology, immunology, medical genetics and pharmaceutics in the division of hematology at the university’s comprehensive cancer center.
 
At City of Hope, Dr. Marcucci is playing a key role in our efforts to further expand and broaden our world-renowned work in leukemia research and treatment. He directs the Gehr Family Center for Leukemia Research, is chief of the Division of Leukemia, and serves as chair of the Department of Hematologic Malignancies Translational Science.
 
A nationally recognized authority on leukemia, Dr. Marcucci has lectured around the world and authored more than 500 scholarly papers on the subject. His ultimate goal is to make leukemia a thing of the past. He has received numerous competitive National Cancer Institute grants for his clinical and research work focused on the pathogenesis, treatment and prognostic assessment of patients with acute myeloid leukemia. Dr. Marcucci currently serves on the editorial board of three journals, including Blood and the Journal of Clinical Oncology.
 
“I know what a devastating disease leukemia can be for patients and their families,” he says. “I would love one day to be able to say that I helped to alleviate their suffering.”

 

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.